
Roberto Mina, MD, associate professor of hematology at the Winship Cancer Institute at Emory University, discussed the significance of the patient population of the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.
Roberto Mina is an associate professor at Winship Cancer Institute of Emory University and former assistant professor at University of Turin in Italy.

Roberto Mina, MD, associate professor of hematology at the Winship Cancer Institute at Emory University, discussed the significance of the patient population of the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.

Roberto Mina, MD, discussed the significance of the early outcomes that were reported from the MajesTEC-9 trial in patients with relapsed/refractory multiple myeloma.